Allspring Global Investments Holdings, LLC Akero Therapeutics, Inc. Transaction History

Allspring Global Investments Holdings, LLC

$62.1 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$41.19 - $52.25 $19,853 - $25,184	482 New	482 $24,000
Q2 2023 Jul 18, 2023	BUY	$36.89 - $56.88 $1,291 - $1,990	35 Added 2.6%	1,382 $64,000
Q1 2023 Apr 13, 2023	SELL	$37.27 - $50.24 $6,894 - $9,294	-185 Reduced 12.08%	1,347 $51,000
Q4 2022 Jan 23, 2023	SELL	$33.44 - $54.8 $1,136 - $1,863	-34 Reduced 2.17%	1,532 $0
Q3 2022 Oct 26, 2022	BUY	$10.15 - $34.05 $15,894 - $53,322	1,566 New	1,566 $53,000

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

Wellington Management Group LLP Boston, MA

7.9M
Shares

$221 Million
0.04% of portfolio
Janus Henderson Group PLC London, X0

7.08M
Shares

$198 Million
0.11% of portfolio
Rtw Investments, LP New York, NY

5.92M
Shares

$166 Million
2.71% of portfolio
Black Rock Inc. New York, NY

5.59M
Shares

$156 Million
0.0% of portfolio
General Atlantic LLC New York, NY

5.23M
Shares

$146 Million
4.29% of portfolio

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.3B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.

Account